Invivyd, Inc. (IVVD) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• InVivid (IVVD) Q1 2026: Pemgarda Climbs 22% as Monoclonal Antibody Platform Expands Beyond COVID
  June 17, 2026
• InVivid (IVVD) Q3 2025: $87M Capital Infusion Powers Pivotal Antibody Launch Path
  June 16, 2026
• InVivid (IVVD) Q4 2025: Pemgarda Revenue Climbs 31% QoQ, Pivotal VYD2311 Data in Sight
  June 15, 2026

Browse all companies